ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has authorised Vocabria (cabotegravir ...

A team of scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg and the University of Regensburg has unveiled insights into how HIV-1, the virus responsible for ...

A team of scientists at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg and the University of Regensburg has unveiled insights into how HIV-1, the virus responsible ...

Scientists have unveiled insights into how HIV-1, the virus responsible for AIDS, skillfully hijacks cellular machinery for its own survival. By dissecting the molecular interplay between the virus ...

Researchers mapped HIV-1’s translation strategy, revealing RNA elements like uORFs, iORFs and an intricate frameshift site ...

在格拉斯哥举行的HIV药物治疗会议上，一份病例报告显示， 一名接受具有罕见突变（该突变可阻止病毒进入细胞）的供体干细胞移植以治疗癌症的患者，可能成为 第八例长期病毒缓解的HIV感染者。

Pseudoscience has recently been reemerging in the US. While much of it concerns vaccines, an "oldie" is again making the rounds: HIV is neither the cause nor the sole cause of AIDS. This nonsense has ...

The HIV-1 Rev protein plays a crucial role in the life cycle of the human immunodeficiency virus (HIV) by facilitating the export of viral RNA from the nucleus to the cytoplasm. This process is ...

来自德国维尔纽斯堡的Helmholtz rna感染研究所（HIRI）和雷根斯堡大学的一组科学家揭示了HIV-1病毒（导致艾滋病的病毒）是如何巧妙地劫持细胞机制以维持自身生存的。通过剖析病毒和宿主之间的分子相互作用，研究人员确定了HIV-1在抑制宿主细胞防御的同时确保其复制的新策略。这项研究发表在《自然结构与分子生物学》杂志上。

编者按：近日，《柳叶刀-HIV》刊载了IV期D2ARLING研究结果。该研究探讨了在未进行基线耐药检测的情况下，使用DTG和3TC二联方案及标准三联方案的病毒学控制率具有非劣效性。二联简化治疗方案为目前重要的研究方向，多种二联简化治疗方案被推荐用于不 ...

首个专门针对清除潜伏HIV-1细胞的T细胞受体（TCR）疗法已经通过了初步临床试验。这种双特异性免疫疗法可以靶向并清除那些长期携带HIV的CD4+细胞，也就是所谓的“病毒储存库”。